Monotherapy using a patient-derived xenograft model of NUP98::NSD1 -rearranged AML caused a highly significant prolongation of survival compared to the vehicle-treated control cohort (median survival 152 vs. 103 days).
1
—
—
Monotherapy using a patient-derived xenograft model of NUP98::NSD1 -rearranged AML caused a highly significant prolongation of survival compared to the vehicle-treated control cohort (median survival 152 vs. 103 days).